Objective: prioritizing the most likely targets for your ligand by using experimental assessment.

Typical project: selectivity profiling: identification of secondary targets for a known hit/lead via proprietary in silico strategies.

Technology: selection of the most likely targets is performed by docking a ligand with our collection of 7,000 active sites from the Protein Databank using a modified version of the GOLD software1. Our post-processing technology selects targets according to automatically computed enrichment rates. Past experience suggests that 20 to 30% of selected proteins are true targets of the ligand under investigation.

Competitive advantage: in silico ligand profiling allows us to simultaneously address potency and selectivity issues at a very competitive price, and thus to anticipate pharmacological side effects for your ligand.

Reference
1.Paul N, Bret G, Kellenberger E, Müller P, Rognan D. (2004) Proteins,  54, 671-680